U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT06918925) titled 'First-In-Human Study to Evaluate Single Ascending Doses of JUV-161 in Healthy Adult Volunteers' on March 24.
Brief Summary: The present First-In-Human (FIH) study (JUV-161-101) aims to assess the safety, tolerability, and pharmacokinetics (PK) of single subcutaneous (SC) doses of JUV-161 in healthy volunteers. The study design is well-established for FIH studies and appropriate to assess the preliminary safety and tolerability of new drug candidates.
Data from this study will support conduct of a multiple-ascending dose (MAD) study in patients with DM1 as well as supporting studies in other degenerative myopathies and other disord...